|
Agenda
Monday, September 8, 2008 |
|
|
7:15 – 8:00 a.m. |
Registration and Continental Breakfast |
|
|
8:00 – 8:15 a.m. |
Welcome and Workshop Introduction
Rob Star, Director, Division of Kidney, Urology, and Hematology Diseases, NIDDK, NIH, Bethesda, MD
Daniel Wright, Molecular Medical Branch, Division of Kidney, Urologic, and Hematologic Disease (DKUH), National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD |
|
|
Overviews: EPO and EPO-R Biology and the Clinical Use of EPO |
|
|
8:15 – 8:45 a.m. |
Overview of EPO Expression and Signaling
H. Frank Bunn, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA |
|
|
8:45 – 9:15 a.m. |
EPO-R Expression
Connie Noguchi, Molecular Medical Branch, NIDDK, NIH, Bethesda, MD |
|
|
9:15 – 9:45 a.m. |
Evolution of EPO Therapy During the Past 20 Years
John Adamson, University of California at San Diego, San Diego, CA |
|
|
9:45 – 10:15 a.m. |
Break |
|
|
Observations From the Clinical Use of EPO Indicating Non-Hematopoietic Effects |
|
Moderator: Daniel Wright, NIDDK, NIH, Bethesda, MD |
|
|
10:15 –10:45 a.m. |
EPO Use in Patients With Renal Failure
Ajay K. Singh, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA |
|
|
10:45 – 11:15 a.m. |
EPO Use in Cancer Patients
Charles L. Bennett, Northwestern University Medical Center, Chicago, IL |
|
|
11:15 – 11:30 a.m. |
Examples of Patients With High Endogenous EPO
Blanche Alter, Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), NIH, Bethesda, MD |
|
|
EPO-R Expression and Function in Cardiovascular Tissues |
|
Moderator: Connie Noguchi, NIDDK, NIH, Bethesda, MD |
|
|
11:30 a.m. – 12:00 p.m. |
Mouse Models for EPO and EPO-R Biology
Norio Suzuki, Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden |
|
|
12:00 – 12:30 p.m. |
EPO Signaling, Vascular Injury, and Tissue Ischemia
Kenneth Maiese, Neurology, Anatomy and Cell Biology, Wayne State University Medical School, Detroit, MI |
|
|
12:30 – 2:00 p.m. |
Lunch (on your own) |
|
|
2:00 – 2:30 p.m. |
Protective and Adverse Physiologic Effects of Excessive EPO
Max Gassmann, Cardiology and Cardiovascular Research, University of Zürich, Switzerland |
|
|
2:30 – 3:00 p.m. |
EPO Function in Endothelial Cells and the Heart
B. Daan Westenbrink, Department of Cardiology, University Medical Center, Groningen, The Netherlands |
|
|
3:00 – 3:30 p.m. |
Evidence for EPO Protection of the Ischemic Heart
Walter Koch, Center for Translational Medicine, Jefferson Medical College, Philadelphia, PA |
|
|
3:30 – 4:00 p.m. |
EPO in Retinal Angiogenesis: Vessel Loss and Proliferation
Jing Chen, Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, MA |
|
|
4:00 – 4:15 p.m. |
Break |
|
|
Concise Presentations - 1 |
|
|
4:15 – 4:30 p.m. |
EPO: A Potent Inducer of Peripheral Immuno/Inflammatory Modulation in Autoimmune EAE
Peter Dowling, University of Medicine and Dentistry of New Jersey, East Orange, NJ |
|
|
4:30 – 4:45 p.m. |
rhEPO Augments Monocyte Chemoattractant Protein-1 Expression and Elevates Serum Asymmetric Dimethylarginine Concentrations: Implications for Atherogenesis in Chronic Kidney Disease
Anjali Desai, University of Michigan Medical School, Ann Arbor, MI |
|
|
4:45 – 5:00 p.m. |
EPO-Rs Are Not Detectable on Endothelial Cells and EPO Does Not Stimulate Angiogenesis
Steve Elliott, Amgen Inc., Thousand Oaks, CA |
|
|
5:00 – 5:15 p.m. |
EPO-R Gene Regulation in Neuronal Cells
Christof Dame, Virchow-Klinikum and Institute of Neuropathology, University of Medizin, Berlin, Germany |
|
|
5:15 – 5:30 p.m. |
Novel EPO-R Response Circuits
D.M. Wojchowski, Maine Medical Center Research Institute, Scarborough, ME |
|
|
5:30 – 6:30 p.m. |
Poster Presentations (followed by dinner on your own) |
|
|
Tuesday, September 9 |
|
|
7:15 – 8:00 a.m. |
Continental Breakfast |
|
|
EPO-R Expression and Function in Neural Tissues |
|
Moderator: Connie Noguchi, NIDDK, NIH, Bethesda, MD |
|
|
8:00 – 8:30 a.m. |
Endogenous EPO Signaling Promotes Normal Neural Progenitor Cell Proliferation
Zhiyong Chen, Walter Reed Army Institute, Institute of Research, Washington, DC |
|
|
8:30 – 9:00 a.m. |
EPO Neuroprotection in Neonates
Sandra Juul, Department of Pediatrics, University of Washington, Seattle, WA |
|
|
9:00 – 9:30 a.m.
|
EPO Protection in Nerve Injury and Degeneration
Ahmet Hoke, Department of Neurology, Johns Hopkins University, Baltimore, MD |
|
|
9:30 – 10:00 a.m. |
Neurorestorative effects of EPO following brain injury
Lie Wang, Department of Neurology, Henry Ford Health Sciences Center, Detroit, MI |
|
|
10:00 – 10:30 a.m. |
Break |
|
|
10:30 – 11:00 a.m. |
EPO Neuroprotection Trials: Stroke and Schizophrenia
Hannelore Ehrenreich, Max Planck Institute, Experimental Medicine, Germany |
|
|
EPO-R Expression and Function in Solid Tumor Neoplasias |
|
Moderator: Murat Arcasoy, Duke University Medical Center, Durham, NC |
|
|
11:00 – 11:30 a.m. |
EPO Effects on Tumor Angiogenesis and Progression
Murat Arcasoy, Hematology-Oncology, Duke University Medical Center, Durham, NC |
|
|
11:30 a.m. – 12:00 p.m. |
EPO Effects in Melanoma Models
Xiaowei Xu, Department of Pathology, University of Pennsylvania, Philadelphia, PA |
|
|
12:00 – 12:30 p.m. |
EPO Signaling in Ovarian and Prostate Cancer
Arthur Sytkowski, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA |
|
|
12:30 – 2:00 p.m. |
Lunch (on your own) |
|
|
2:00 – 2:30 p.m. |
Predictive Testing for EPO-induced Tumor Progression in Patients With Head and Neck Cancer
Chris Miller and C. Anthony Blau, University of Washington, Seattle, WA |
|
|
Concise Presentations - 2 |
|
|
2:30 – 2:45 p.m. |
Role of the EPO-R in Tumorigenesis
T.R.J. Lappin, Centre for Cancer Research & Cell Biology, Queen’s University, Belfast, Northern Ireland |
|
|
2:45 – 3:00 p.m. |
Expression of EPO-R by Mammary Epithelial Cells Results in a Premalignant Phenotype
Laurie Feldman, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA |
|
|
Closing Perspectives and Discussion |
|
|
3:00 – 3:30 p.m. |
Hematopoietic Versus Non-Hematopoietic Activities of EPO
Harvey Lodish, Whitehead Institute, Massachusetts Institute of Technology (MIT), Boston, MA |
|
|
3:30 p.m. |
Workshop Adjourns |
|
|
|
![](images/spacer.gif) |